The Frequency of Epidermal Growth Factor Receptor (EGFR) Mutations in Iraqi Patients with Non-Small Cell Lung Cancer (NSCLC)

Overview

Journal Asian Pac J Cancer Prev

Specialty Oncology

Date 2021 Feb 28

PMID 33639678

Citations 4

Authors

Hanan H Ramadhan

Dhuha F Taaban

Jubran K Hassan

Affiliations

Soon will be listed here.

Abstract

Objective: Non-Small Cell Lung Cancer (NSCLC) Carcinogenesis could be caused by numerous genetic mutations, one of the most common is the mutation in the Epidermal Growth Factor Receptor (EGFR) which was used in the advanced stages of the disease as a therapeutic goal. This study aim to estimate the frequency of Epidermal Growth Factor Receptor mutations in Iraqi patients with Non-Small Cell Lung Cancer.

Methods: One hundred thirty-eight patients confirmed with NSCLC have participated in this study, patients were sent for EGFR testing by different oncology centers in Iraq. Data and samples were collected. The Mutation was detected using COBAS® DNA Sample Preparation Kit that designed to detect the following mutations: Exon 19: deletions and complex mutations; Exon 21: L861Q and L858R; Exon 18 mutation: G719X (G719A, G719C, and G719S); Exon 20: S768I, T790M, and insertions, this kit utilizes the technology of the real time Polymerase Chain Reaction.

Results: This study was included 79 males and 59 females, with a mean age of 60.1±12.4 years. A positive EGFR mutations were found in 38 (27.53%) of samples. Exon 19 deletions (25/38, 65.8%) and substitution L858R in exon 21 10/38 (26.3%) were the most common mutations. Multiple mutations (Exon 20 and 19 combined together) were founded in 2/38 (5.3%), 1/38 (2.6%) ALK mutation. Non-significant differences among age groups and gender in the incidence of mutations were found.

Conclusion: The current study represents the first epidemiological study in Iraq to find EGFR mutations frequency among NSCLC patients that reveals the incidence rate of 27.53%, which is between the higher prevalence rate in Asian populations and lower rates in western countries. These results explain the genetic differences of NSCLC in the world due to ethnic differences of the population, more studies are needed in Arab countries to study the EGFR mutations, find the effect of ethnicity and environmental factors for lung cancer, and the subsequent therapy.

Citing Articles

Molecular analysis of genetic mutations in non-small cell lung cancer in Morocco.

Morjani O, Benkirane N, Errihani H, Elfahime E, Lakhiari H Pan Afr Med J. 2024; 47:116.

PMID: 38828424 PMC: 11143076. DOI: 10.11604/pamj.2024.47.116.42973.

Long-term survival after stereotactic body radiotherapy combined with immunotherapy plus anti-angiogenesis therapy in patients with advanced non-small cell lung cancer and exon 20 insertion mutation: a report of two cases.

Luo Q, Chen L, Li Z, Cheng L, Zhang S, Zong Y Transl Lung Cancer Res. 2023; 12(11):2330-2341.

PMID: 38090524 PMC: 10713269. DOI: 10.21037/tlcr-23-542.

Non-Small Cell Lung Cancer: Targetable Variants in Concurrent Tissue and Liquid Biopsy Testing in a North Indian Cohort.

Paturu R, Lingaiah R, Kumari N, Singh S, Krishnani N, Srivastava S Asian Pac J Cancer Prev. 2023; 24(10):3467-3475.

PMID: 37898852 PMC: 10770664. DOI: 10.31557/APJCP.2023.24.10.3467.

Advanced Non-small Cell Lung Cancer: EGFR Mutation Analysis Using Pyrosequencing and the Fully Automated qPCR-Based Idylla System.

Boustany Y, Laraqui A, El Zaitouni S, Ghaouti M, Benzekri A, Kettani F Cancer Control. 2023; 30:10732748231177538.

PMID: 37196225 PMC: 10196548. DOI: 10.1177/10732748231177538.

References

Naderi S, Ghorra C, Haddad F, Kourie H, Rassy M, El Karak F . EGFR mutation status in Middle Eastern patients with non-squamous non-small cell lung carcinoma: A single institution experience. Cancer Epidemiol. 2015; 39(6):1099-102. DOI: 10.1016/j.canep.2015.08.016. View

Benbrahim Z, Antonia T, Mellas N . EGFR mutation frequency in Middle East and African non-small cell lung cancer patients: a systematic review and meta-analysis. BMC Cancer. 2018; 18(1):891. PMC: 6137870. DOI: 10.1186/s12885-018-4774-y. View

Fakhruddin N, Mahfouz R, Farhat F, Tfayli A, Abdelkhalik R, Jabbour M . Epidermal growth factor receptor and KRAS mutations in lung adenocarcinoma: a retrospective study of the Lebanese population. Oncol Rep. 2014; 32(5):2223-9. DOI: 10.3892/or.2014.3406. View

Szumera-Cieckiewicz A, Olszewski W, Tysarowski A, Kowalski D, Glogowski M, Krzakowski M . EGFR mutation testing on cytological and histological samples in non-small cell lung cancer: a Polish, single institution study and systematic review of European incidence. Int J Clin Exp Pathol. 2013; 6(12):2800-12. PMC: 3843260. View

Zhou Y, Yang Y, Yang C, Chen Y, Yang C, Du Y . Epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) of Yunnan in southwestern China. Oncotarget. 2017; 8(9):15023-15033. PMC: 5362464. DOI: 10.18632/oncotarget.14706. View

Goldstraw P, Ball D, Jett J, Le Chevalier T, Lim E, Nicholson A . Non-small-cell lung cancer. Lancet. 2011; 378(9804):1727-40. DOI: 10.1016/S0140-6736(10)62101-0. View

Kota R, Gundeti S, Gullipalli M, Linga V, Maddali L, Digumarti R . Prevalence and outcome of epidermal growth factor receptor mutations in non-squamous non-small cell lung cancer patients. Lung India. 2015; 32(6):561-5. PMC: 4663857. DOI: 10.4103/0970-2113.168099. View

Midha A, Dearden S, McCormack R . EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). Am J Cancer Res. 2015; 5(9):2892-911. PMC: 4633915. View

Reinersman J, Johnson M, Riely G, Chitale D, Nicastri A, Soff G . Frequency of EGFR and KRAS mutations in lung adenocarcinomas in African Americans. J Thorac Oncol. 2010; 6(1):28-31. PMC: 3337520. DOI: 10.1097/JTO.0b013e3181fb4fe2. View

10.

Berois N, Touya D, Ubillos L, Bertoni B, Osinaga E, Varangot M . Prevalence of EGFR Mutations in Lung Cancer in Uruguayan Population. J Cancer Epidemiol. 2017; 2017:6170290. PMC: 5506465. DOI: 10.1155/2017/6170290. View

11.

Liu Y, Ren Z, Wang J, Zhang S . Epidermal growth factor receptor-tyrosine kinase inhibitor therapy is especially beneficial to patients with exon 19 deletion compared with exon 21 L858R mutation in non-small-cell lung cancer: Systematic review and meta analysis. Thorac Cancer. 2016; 7(4):406-14. PMC: 4930959. DOI: 10.1111/1759-7714.12343. View

12.

A D, A Y, N K, F B, Ag D, Er K . The Frequency of EGFR and KRAS Mutations in the Turkish Population with Non-small Cell Lung Cancer and their Response to Erlotinib Therapy. Balkan J Med Genet. 2019; 21(2):21-26. PMC: 6454234. DOI: 10.2478/bjmg-2018-0022. View

13.

Dearden S, Stevens J, Wu Y, Blowers D . Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap). Ann Oncol. 2013; 24(9):2371-6. PMC: 3755331. DOI: 10.1093/annonc/mdt205. View

14.

Palacio S, Pontes L, Prado E, Arshad J, Ali R, Piha T . Mutation Testing: Changing Patterns of Molecular Testing in Brazil. Oncologist. 2018; 24(4):e137-e141. PMC: 6459254. DOI: 10.1634/theoncologist.2018-0254. View

15.

Zhou W, Christiani D . East meets West: ethnic differences in epidemiology and clinical behaviors of lung cancer between East Asians and Caucasians. Chin J Cancer. 2011; 30(5):287-92. PMC: 4013393. DOI: 10.5732/cjc.011.10106. View

16.

Jackman D, Yeap B, Sequist L, Lindeman N, Holmes A, Joshi V . Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res. 2006; 12(13):3908-14. DOI: 10.1158/1078-0432.CCR-06-0462. View

17.

Errihani H, Inrhaoun H, Boukir A, Kettani F, Gamra L, Mestari A . Frequency and type of epidermal growth factor receptor mutations in moroccan patients with lung adenocarcinoma. J Thorac Oncol. 2013; 8(9):1212-4. DOI: 10.1097/JTO.0b013e31829f6b4a. View

18.

Shi Y, Au J, Thongprasert S, Srinivasan S, Tsai C, Khoa M . A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol. 2014; 9(2):154-62. PMC: 4132036. DOI: 10.1097/JTO.0000000000000033. View

19.

Al-Kuraya K, Siraj A, Bavi P, Al-Jommah N, Ezzat A, Sheikh S . High epidermal growth factor receptor amplification rate but low mutation frequency in Middle East lung cancer population. Hum Pathol. 2006; 37(4):453-7. DOI: 10.1016/j.humpath.2005.12.004. View

20.

Cote M, Haddad R, Edwards D, Atikukke G, Gadgeel S, Soubani A . Frequency and type of epidermal growth factor receptor mutations in African Americans with non-small cell lung cancer. J Thorac Oncol. 2011; 6(3):627-30. PMC: 3057407. DOI: 10.1097/JTO.0b013e31820a0ec0. View